These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9855502)

  • 41. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
    Appleyard ME; McDonald B
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1074-8. PubMed ID: 1469405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients.
    D'Aniello A; Fisher G; Migliaccio N; Cammisa G; D'Aniello E; Spinelli P
    Neurosci Lett; 2005 Nov; 388(1):49-53. PubMed ID: 16039064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular abnormalities in autopsied brain tissue from the inferior horn of the lateral ventricles of nonagenarians and Alzheimer disease patients.
    Pearson A; Ajoy R; Crynen G; Reed JM; Algamal M; Mullan M; Purohit D; Crawford F; Ojo JO
    BMC Neurol; 2020 Aug; 20(1):317. PubMed ID: 32854643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease.
    Ewers M; Cheng X; Zhong Z; Nural HF; Walsh C; Meindl T; Teipel SJ; Buerger K; He P; Shen Y; Hampel H
    J Alzheimers Dis; 2011; 25(2):373-81. PubMed ID: 21460439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach.
    Newman SF; Sultana R; Perluigi M; Coccia R; Cai J; Pierce WM; Klein JB; Turner DM; Butterfield DA
    J Neurosci Res; 2007 May; 85(7):1506-14. PubMed ID: 17387692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.
    Vuletic S; Peskind ER; Marcovina SM; Quinn JF; Cheung MC; Kennedy H; Kaye JA; Jin LW; Albers JJ
    J Neurosci Res; 2005 May; 80(3):406-13. PubMed ID: 15795933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients.
    Takeda S; Commins C; DeVos SL; Nobuhara CK; Wegmann S; Roe AD; Costantino I; Fan Z; Nicholls SB; Sherman AE; Trisini Lipsanopoulos AT; Scherzer CR; Carlson GA; Pitstick R; Peskind ER; Raskind MA; Li G; Montine TJ; Frosch MP; Hyman BT
    Ann Neurol; 2016 Sep; 80(3):355-67. PubMed ID: 27351289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of Aldh2 (-/-) mice as an age-related model of cognitive impairment and Alzheimer's disease.
    D'Souza Y; Elharram A; Soon-Shiong R; Andrew RD; Bennett BM
    Mol Brain; 2015 Apr; 8():27. PubMed ID: 25910195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An aberrant protein complex in CSF as a biomarker of Alzheimer disease.
    Lovell MA; Lynn BC; Xiong S; Quinn JF; Kaye J; Markesbery WR
    Neurology; 2008 Jun; 70(23):2212-8. PubMed ID: 18448869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease.
    Begni B; Brighina L; Sirtori E; Fumagalli L; Andreoni S; Beretta S; Oster T; Malaplate-Armand C; Isella V; Appollonio I; Ferrarese C
    Free Radic Biol Med; 2004 Sep; 37(6):892-901. PubMed ID: 15304259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain.
    Lovell MA; Xie C; Markesbery WR
    Brain Res; 2000 Feb; 855(1):116-23. PubMed ID: 10650137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
    Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
    Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease.
    Butterfield DA; Reed TT; Perluigi M; De Marco C; Coccia R; Keller JN; Markesbery WR; Sultana R
    Brain Res; 2007 May; 1148():243-8. PubMed ID: 17395167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
    Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid peroxidation in aging brain and Alzheimer's disease.
    Montine TJ; Neely MD; Quinn JF; Beal MF; Markesbery WR; Roberts LJ; Morrow JD
    Free Radic Biol Med; 2002 Sep; 33(5):620-6. PubMed ID: 12208348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mercapturate metabolism of 4-hydroxy-2-nonenal in rat and human cerebrum.
    Sidell KR; Montine KS; Picklo MJ; Olsen SJ; Amarnath V; Montine TJ
    J Neuropathol Exp Neurol; 2003 Feb; 62(2):146-53. PubMed ID: 12578224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.
    Perluigi M; Sultana R; Cenini G; Di Domenico F; Memo M; Pierce WM; Coccia R; Butterfield DA
    Proteomics Clin Appl; 2009 Jun; 3(6):682-693. PubMed ID: 20333275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.